You have accessJournal of UrologyProstate Cancer: Localized VII1 Apr 20121474 THE IMPACT OF UPGRADING IN PATIENTS CANDIADTES FOR ACTIVE SURVEILLANCE Francisco Comez-Veiga, Sara Breijo, Sonia Pertega, Anton Zarraonaindia, Javier Casas, Iyahd Barghouty, Luis Busto, Juan Dacal, Jose Ponce, Salvador Pita, and V. Ch. Abal Francisco Comez-VeigaFrancisco Comez-Veiga University Hospital a Coruña, Spain More articles by this author , Sara BreijoSara Breijo A Coruña, Spain More articles by this author , Sonia PertegaSonia Pertega A Coruña, Spain More articles by this author , Anton ZarraonaindiaAnton Zarraonaindia A Coruña, Spain More articles by this author , Javier CasasJavier Casas A Coruña, Spain More articles by this author , Iyahd BarghoutyIyahd Barghouty A Coruña, Spain More articles by this author , Luis BustoLuis Busto A Coruña, Spain More articles by this author , Juan DacalJuan Dacal A Coruña, Spain More articles by this author , Jose PonceJose Ponce A Coruña, Spain More articles by this author , Salvador PitaSalvador Pita A Coruña, Spain More articles by this author , and V. Ch. AbalV. Ch. Abal A Coruña, Spain More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.1995AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Due to the migration of clinical stages now see a larger number of patients with low tumor burden increasingly we emphasize the need for active treatments with their associated side effects. The aim of this study is analyze the cancer outcomes and the impact of upgrading in a series of patients who are candidates for active monitoring using the PRIAS criteria (P) and those undergoing radical prostatectomy (RP) using the START (S) criteria. METHODS In the period between June 1999 and December 2008, 687 patients who no received neo-adjuvant or adjuvant treatment were included. Prostate cancer diagnosis was obtained by ultrasound-guided 10-core biopsy and PSA test, before rectal examination. We used the Gleason classification for clinical and pathological stage and TNM 2009 for clinical staging. We selected patients who met the criteria for AS as criteria P ‘PSA <10, PSADT ≤ 0.2, CT1, CT2, Gleason ≤ 6, ≤ 2 core positive biopsy', or S, ‘PSA <10, 0.05. Table. CONCLUSIONS A significant proportion of patients eligible for active follow-up in both studies may have adverse pathological findings, and high incidence of progression but the impact and over all progression appear not be significant. All these data indicate that the selection of candidates for active monitoring, pending the results of clinical trials has to be careful. We need new diagnostic tools that allow us to better define the aggressiveness of prostate tumors. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e597-e598 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Francisco Comez-Veiga University Hospital a Coruña, Spain More articles by this author Sara Breijo A Coruña, Spain More articles by this author Sonia Pertega A Coruña, Spain More articles by this author Anton Zarraonaindia A Coruña, Spain More articles by this author Javier Casas A Coruña, Spain More articles by this author Iyahd Barghouty A Coruña, Spain More articles by this author Luis Busto A Coruña, Spain More articles by this author Juan Dacal A Coruña, Spain More articles by this author Jose Ponce A Coruña, Spain More articles by this author Salvador Pita A Coruña, Spain More articles by this author V. Ch. Abal A Coruña, Spain More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

From the Departments of Radiology (M. J. Díaz Candamio, F. Pombo), Pathology (F. Arnal), and Urology (L. Busto), Hospital Juan Canalejo, La Coruña, Spain. Address correspondence and reprint request to Dr. M. J. Díaz Candamio, Servicio de Radiología, Hospital Juan Canalejo, Xubias de Arriba 84, 15006 La Coruña, Spain.